|
|
|
| Diagnostic value of serum oxaphosphatase 1 level in α-fetoprotein negative primary liver cancer |
| ZHU Bo WU Junrong SHU Hong HUANG Zhaodong LIANG Yihua ZHAO Huiliu |
| Clinical Laboratory, the Affiliated Cancer Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning 530021, China |
|
|
|
Abstract Objective To evaluate the diagnostic value and the threshold value of paraoxonase 1 (PON1) in α-fetoprotein negative primary liver cancer (AFP-PHC). Methods From January to December 2015, serum samples of 60 AFP negative cirrhosis patients (AFP-LC group) and 46 AFP-PHC patients (AFP-PHC group) hospitalized in the Affiliated Cancer Hospital of Guangxi Medical University were collected. The serum AFP levels of all included subjects were detected by electrochemoluminescence immunoassay, and PON1 levels were detected by enzyme-linked immunoassay. Results The serum PON1 level in the AFP-PHC group was significantly lower than that in the AFP-LC group, and the difference was statistically significant (P ＜ 0.05), the maximum area under the subject operating characteristic curve for diagnosis of AFP-PHC by PON1 level was 0.768. When PON1 level ＜ 234.31 pg/mL, the sensitivity and specificity of the diagnosis of AFP-PHC were 71.7% and 73.9% respectively. There was no correlation between serum PON1 level and liver function grade, pathological differentiation degree, tumor thrombus or positive hepatitis B surface antigen in patients with AFP-PHC (P > 0.05). Conclusion Serum PON1 level is effective is diagnosing AFP-PHC.
|
|
|
|
|
|
[1] Mackness B，Durrington PN，Mackness MI. Human serum paraoxonase [J]. General Pharmacology，1998，31（3）：329-336.
[2] van Himbergen TM，van Tits LJ，Roest M，et al. The story of PON1：how an organophosphate-hydrolysing enzyme is becoming a player in cardiovascular medicine [J]. Neth J Med，2006，64（2）：34-38.
[3] Akk?覦z H，Kuran S，Akg?觟llü E，et al. Effect of PON1 gene polymorphisms in Turkish patients with hepatocellular carcinoma [J]. Meta Gene，2013，1：93-101.
[4] Mackness M，Mackness B. Targeting paraoxonase-1 in atherosclerosis [J]. Expert Opin Ther Targets，2013，17（7）：829-837.
[5] Gaál K，Tarr T，L■rincz H，et al. High-density lipopoprotein antioxidant capacity，subpopulation distribution and paraoxonase-1 activity in patients with systemic lupus erythematosus [J]. Lipids Health Dis，2016，15：60.
[6] 吴曾繁，吴剑胜，胡雪松，等.PON1基因多态性和冠心病关系的研究进展[J].医学综述，2010，16（3）：321-324.
[7] 阴文丽，潘国忠.对氧磷酶1（PON1）及其基因多态性与动脉粥样硬化的关系[J].中国心血管病研究，2014，12（1）：67-69.
[8] 中华医学会传染病与寄生虫病学分会·肝病学分会.病毒性肝炎防治方案[J].肝脏，2000，6（1）：65-67.
[9] 中华人民共和国卫生部.原发性肝癌诊疗规范（2011年版）[J].肿瘤学杂志，2011，16（10）：929-946.
[10] Camps J，Marsillach J，Joven J. Measurement of serum paraoxonase-1 activity in the evaluation of liver function [J]. World J Gastroenterol 2009，15（16）：1929-1933.
[11] Mackness B，Quarck R，Verreth W，et al. Human paraoxonase-1 overexpression inhibits atherosclerosis in a mouse model of metabolic syndrome [J]. Arterioscler Thromb Vasc Biol，2006，26（7）：545-550.
[12] Tavori H，Aviram M，Khatib S，et al. Human carotid lesion linoleic acid hydroperoxide inhibits paraoxonase 1 （PON1） activity via reaction with PON1 free sulfhydryl cysteine 284 [J]. Free Radic Biol Med，2011，50（1）：148-156.
[13] 舒宏.乙肝病毒相关肝病血清分子标志物的筛选、验证和诊断价值[D].上海：复旦大学，2011.
[14] Devarajan A，Shih D，Ｒeddy ST. Inflammation，infection，cancer and all that the role of paraoxonases [J]. Adv Exp Med Biol，2014，8（24）：33-41.
[15] 蒋兴亮，张晓岚，周京国，等.血浆对氧磷酯酶1活性与肝硬化Child-Pugh分级的关系[J].国际检验医学杂志，2008，29（10）：880-882.
[16] Zhou C，Cao J，Shang L，et al. Reduced paraoxonase 1 activity as a marker for severe coronary artery disease [J]. Dis Markers，2013，35（2）：97-103．
[17] Gugliucci A. Activation of paraoxonase 1 is associated with HDL remodeling ex vivo [J]. Clin Chim Acta，2014，4（29）：38-45．
[18] Gaidukov L，Tawfik DS. High affinity，stability，and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I [J]. Biochemistry，2005，44（35）：843-854.
[19] Elkiran ET，Mar N，Aygen B，et al. Serum paraoxonase and arylesterase activities in patients with lung cancer in a Turkish population [J]. BMC Cancer，2007，7：48-54.
[20] Stevens VL，Rodriguez C，Pavluck AL，et al. Association of polymorphisms in the paraononase 1 gene with breast cancer incidence in the CPS-Ⅱ Nutrition Cohort [J]. Cancer Epidemiol Biomarkers Prev，2006，15（6）：1226-1228.
[21] Akcay MN，Yilmaz I，Polat MF，et al. Serum paraoxonase levels in gastric cancer [J]. Hepato-gastroenterology，2003，50（2）：ccxxv-ccxxvii.
[22] Leviev I，Deakin S，James RW. Decreased stability of the M54 isoform of paraoxonase as a contributory factor to variations in human serum paraoxonase concentrations [J]. J Lipid Res，2001，42（4）：528-535. |
|
|
|
